A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Public ClinicalTrials.gov record NCT07029945. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study aims to evaluate the safety and efficacy of BRX011, an oral medication, taken once daily by participants with geographic atrophy secondary to age-related macular degeneration. The study is conducted in phases 1 and 2, focusing on assessing both safety (tolerability) and effectiveness (efficacy) of the treatment. Participants: Adults with geographic atrophy due to age-related macular degeneration. Treatment: BRX011 or Placebo is taken once daily as per the protocol. Duration: The study involves multiple visits over 96 weeks to monitor participants' health and response to treatment. Safety Monitoring: Regular checks for adverse events and health status to ensure participant well-being. Checks will include examination of vital signs, clinical labs, ocular exams, and ocular imaging. Primary Outcome Measure: Efficacy of BRX011 in the annual rate of change in the square root of GA area, as specified in the protocol.
Study identification
- NCT ID
- NCT07029945
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 152 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2026 (Estimated)
- Primary completion
- Apr 2029 (Estimated)
- Completion
- Apr 2029 (Estimated)
- Last update posted
- Sep 23, 2026
2026 – 2029
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Associated Retina Consultants - PHX | Gilbert | Arizona | 85020 | Recruiting |
| Associated Retina Consultants | Phoenix | Arizona | 85020 | Recruiting |
| Retina Specialists of Mississippi - Hattiesburg | Hattiesburg | Mississippi | 39402 | Not yet recruiting |
| Sierra Eye Associates | Reno | Nevada | 89502 | Not yet recruiting |
| Retina Associates of Cleveland - Beachwood | Beachwood | Ohio | 44122 | Recruiting |
| Retina Associates of Cleveland | Cleveland | Ohio | 44121 | Not yet recruiting |
| Retina Associates of Cleveland - Middleburg Heights | Middleburg Heights | Ohio | 44130 | Not yet recruiting |
| Retina Research Institute of Texas | Abilene | Texas | 79606 | Recruiting |
| Valley Retina Institute, PA | McAllen | Texas | 78503 | Recruiting |
| Retina Research Center of Southern Utah | St. George | Utah | 84790 | Not yet recruiting |
| Spokane Eye Clinic | Spokane | Washington | 99204 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07029945, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 23, 2026 · Synced Sep 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07029945 live on ClinicalTrials.gov.